Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 4, 2006, Pages 409-415

  Worsham, Maria J ^a   Kang, Mei Chen ^a   Tiwari, Nivedita ^a   Pals, Gerard ^b   Schouten, Jan P ^c   Sethi, Seema ^a   Benninger, Michael S ^a  

^a HENRY FORD HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MRC HOLLAND   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2A; CYCLIN DEPENDENT KINASE 2B; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P16INK4B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; ASSAY; CANCER CELL CULTURE; CHROMOSOME 9P; CONTROLLED STUDY; EXON; GENE DELETION; GENE LOCUS; GENE LOSS; GENE MAPPING; GENE STRUCTURE; HEAD AND NECK CARCINOMA; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN CHROMOSOME; HUMAN TISSUE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION ASSAY; MUTATION; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; GENE DELETION; GENE SILENCING; GENES, P16; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33645863773     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.4.409     Document Type: Article

References (41)

1. Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck. Genes Chromosomes Cancer. 1994;9:192-206.
2. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC. p16 Mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol. 1999;119:285-288.
3. Lydiatt WM, Davidson BJ, Schantz SP, Caruana SC, Chaganti RS. 9p21 Deletion correlates with recurrence in head and neck cancer. Head Neck. 1998;20:113-118.
4. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
5. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.
6. Haber DA. Splicing into senescence: the curious case of p16 and p19ARF. Cell. 1997;91:555-558.
7. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5:2704-2713.
8. Sherr CJ. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
9. INK4B Is a potential effector of TGF-β-induced cell cycle arrest. Nature. 1994;371:257-261.
10. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol. 2001;37:498-504.
11. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42-55.
12. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260-1266.
13. Rocco JW, Li D, Liggett WH, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res. 1998;4:1697-1704.
14. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res. 2002;62:6639-6644.
15. Harasawa H, Yamada Y, Kudoh M, et al. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). Leukemia. 2002;16:1799-1807.
16. Efferth T, Miyachi H, Drexler HG, Gebhart E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol Dis. 2002;28:47-56.
17. Chen YJ, Lin SC, Kao T, et al. Genome-wide profiling of oral squamous cell carcinoma. J Pathol. 2004;204:326-332.
18. Nobori T, Takabayashi K, Tran P, et al. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A. 1996;93:6203-6208.
19. Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res. 1989;49:6098-6107.
20. Bradford CR, Kimmel KA, Van Dyke DL, et al. 11p deletions and breakpoints in squamous cell carcinoma: association with altered reactivity with the UM-E7 antibody. Genes Chromosomes Cancer. 1991;3:272-282.
21. Worsham MJ, Pals G, Schouten J, et al. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:702-708.
22. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
23. Liu TJ, Zhang WW, Taylor DL, et al. Growth suppression of tumor cells of human head and neck cancer cells by the introduction of wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994;54:3662-3667.
24. Sumantran VN, Ealovega MW, Nunez G, et al. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 1995;55:2507-2510.
25. Hoffmann T, Hafner D, Ballo H, et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 1997;17:4419-4425.
26. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7:1204-1213.
27. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18:47S-53S.
28. Toohey JI. Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells. Biochem Biophys Res Commun. 1978;83:27-35.
29. Trackman PC, Abeles RH. Methionine synthesis from 5′-S-methylthioadenosine: resolution of enzyme activities and identification of 1-phospho-5-S methylthioribulose. J Biol Chem. 1983;258:6717-6720.
30. Kamatani N, Nelson-Rees WA, Carson DA. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci U S A. 1981;78:1219-1223.
31. Olopade OI, Pomykala HM, Hagos F, et al. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995;92:6489-6493.
32. Schmid M, Malicki D, Nobori T, et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene. 1998;17:2669-2675.
33. Della Ragione F, Russo G, Oliva A, et al. 5′-Deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene. 1995;10:827-833.
34. Stadler WM, Sherman J, Bohlander SK, et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res. 1994;54:2060-2063.
35. Garcia-Castellano JM, Villanueva A, Healey JH, et al. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res. 2002;8:782-787.
36. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995;11:210-212.
37. Brat DJ, James CD, Jedlicka AE, et al. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol. 1999;154:1431-1438.
38. Chen ZH, Olopade OI, Savarese TM. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol. 1997;52:903-911.
39. Myers RW, Abeles RH. Conversion of 5-S-methyl-5-thio-D-ribose to methionine in Klebsiella pneumoniae: stable isotope incorporation studies of the terminal enzymatic reactions in the pathway. J Biol Chem. 1990;265:16913-16921.
40. O'Shaughnessy JA, Demers LM, Jones SE, et al. α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res. 1999;5:3438-3444.
41. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine: N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000;6:3878-3884.